Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury

Tomer Begaz*, Demetrios Kyriacou, Jordana Segal, Jeffrey J. Bazarian

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

90 Scopus citations


Mild traumatic brain injury (MTBI) is a major public health problem in the United States. A significant subset of MTBI patients develop persistent and distressing neurological, cognitive, and behavioral symptoms, known as the post-concussion syndrome (PCS). To date, multiple studies have assessed the relationship between brain-related proteins found in the serum at the time of injury, and the development of PCS. We conducted a systematic review of prospective cohort studies that assessed the ability of serum biochemical markers to predict PCS after MTBI. A total of 11 studies assessing three different potential biochemical markers of PCS-S100 proteins, neuron-specific enolase (NSE), and cleaved Tau protein (CTP)-met selection criteria. Of these markers, S100 appeared to be the best researched. We conclude that no biomarker has consistently demonstrated the ability to predict PCS after MTBI. A combination of clinical factors in conjunction with biochemical markers may be necessary to develop a comprehensive decision rule that more accurately predicts PCS after MTBI.

Original languageEnglish (US)
Pages (from-to)1201-1210
Number of pages10
JournalJournal of Neurotrauma
Issue number8
StatePublished - Aug 1 2006


  • Biochemical markers
  • Closed head injury
  • Concussion
  • Post-concussion syndrome
  • S100
  • Traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury'. Together they form a unique fingerprint.

Cite this